Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
94643 trials found · Page 137 of 4733
-
New theranostic approach targets brain metastases in solid tumors
Disease control Not yet recruitingThis trial will evaluate treatment for patients with solid tumors with active brain metastases. Patients will be treated with a theranostic or diagnostic agent. Theranostic agents are targeted radioactive drugs used to identify (diagnose) and to deliver therapy. The main purpose …
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New hope for hard-to-treat lung cancer: targeted therapy MK-1084 enters trial
Disease control Recruiting nowResearchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * Ab…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Hope for rare liver disease: new drug trial aims to slow damage
Disease control Recruiting nowThe purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants with Primary sclerosing cholangitis (PSC). PSC is a rare disease that causes inflammation and scarring of the bile ducts in the liver. Over time, this can lead…
Phase: PHASE3 • Sponsor: Ipsen • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug duo takes on deadly brain cancer
Disease control Not yet recruitingThis is a phase IB/II, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment wit…
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Nasal spray could reverse sudden vision loss in major trial
Disease control Not yet recruitingThis is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION. Approximately 272 participants who meet all eligibility criteria will b…
Phase: PHASE3 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New CAR-T therapy aims to tackle tough lymphoma
Disease control Recruiting nowTo evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug combo targets Hard-to-Treat lung cancer
Disease control Not yet recruitingThis is a phase II, open-label, single-arm study evaluating the efficacy and safety of SHR-A1811 (a HER2-targeted ADC) combined with AK112 (a PD-1/VEGF bispecific antibody) in patients with HER2-amplified or overexpressed locally advanced or metastatic NSCLC.
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New Triple-Drug attack shows promise against tough blood cancer
Disease control Not yet recruitingThis is a Phase I/II, single-arm, open-label clinical trial evaluating the safety and preliminary efficacy of a novel induction regimen combining Venetoclax, Azacitidine, and Liposomal Mitoxantrone (VAM) in adult patients with newly diagnosed Acute Myeloid Leukemia (AML) who are …
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New clip surgery could help diabetes patients who Can't get standard treatment
Disease control Recruiting nowThis study evaluates a new surgical device - the Metallic Anastomotic Clip (MAC) - for performing a laparoscopic bypass gastroenteroanastomosis with entero-enteric anastomosis (transit bipartition / "dual-path" procedure) in patients with type 2 diabetes mellitus (T2DM) who have …
Phase: NA • Sponsor: The Society of Bariatric and Metabolic Surgeons of Kazakhstan • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New drug RC288 targets Hard-to-Treat tumors in early trial
Disease control Not yet recruitingThe primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;
Phase: PHASE1, PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Could a simple add-on drug boost stroke recovery after clot removal?
Disease control Not yet recruitingStroke is a leading cause of global mortality and morbidity, with acute ischemic stroke (AIS) accounting for approximately 65.3% of cases and resulting in roughly 3.4 million new cases annually in China. While endovascular thrombectomy (EVT) is the recommended first-line therapy …
Phase: PHASE4 • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC
-
New drug combo before surgery may cut liver cancer recurrence
Disease control Not yet recruitingPostoperative recurrence remains a major limitation to long-term survival in hepatocellular carcinoma (HCC). In addition, a narrow surgical margin is widely regarded as a risk factor for recurrence. Neoadjuvant therapy may represent a strategy to reduce the risk of recurrence, th…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
New immune cell therapy takes on advanced cancers
Disease control Not yet recruitingThis study adopts a single-center, single-arm, open-label design. It aims to evaluate the safety and tolerability of GT307 in patients with advanced solid tumors, as well as assess its pharmacokinetic profile and efficacy, and determine the optimal dosage regimen.
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated May 15, 2026 15:22 UTC
-
New combo therapy aims to stop liver cancer from coming back after surgery
Disease control Not yet recruitingThis study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with high-risk features. (1) Evaluate for some high-risk patient…
Phase: PHASE1, PHASE2 • Sponsor: BinYong Liang • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo aims to shrink melanoma before surgery
Disease control Not yet recruitingThis is a phase II, open label clinical trial determining efficacy of Fianlimab in combination with Cemiplimab in subjects with Melanoma. These are subjects who will have surgery to remove their cancer.
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New targeted drug shows promise for Hard-to-Treat lung cancer
Disease control Not yet recruitingNon-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targets specific proteins on cancer cells. If the cancer gets worse, the next main treatment is usually a medicine called doce…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New transplant strategy aims to stop AML from coming back
Disease control Not yet recruitingThis is a prospective, single-center, observational study to evaluate the efficacy and safety of salvage haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) combined with post-transplant relapse prevention strategies in patients with relapsed/refractory…
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Smart scans and DNA tests aim to boost breast cancer remission
Disease control Not yet recruitingAlthough neoadjuvant dual anti-HER2-targeted therapy, pertuzumab and trastuzumab, combined with taxanes increased the pCR rate for patients with early-stage HER2-positive breast cancer when compared with single blockade combined with chemotherapy, certain patients did not achieve…
Phase: PHASE2 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New radiation strategy aims to wipe out rectal tumors in 7 out of 10 patients
Disease control Not yet recruitingThe aim of this clinical study is to increase the rate of pathological responses up to 70% by means of improved patient selection operated by a radiobiological index called ERI\_TCP and by an increase in the dose of radiotherapy in the final concomitant boost of preoperative radi…
Phase: NA • Sponsor: IRCCS San Raffaele • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
AI could help doctors pick the right treatment for early liver cancer
Knowledge-focused Not yet recruitingThis study aims to address the issue of a lack of individualized basis for selecting liver resection (LH) or microwave ablation (MWA) in early-stage hepatocellular carcinoma (HCC) patients to reduce the early recurrence rate (≤2 years). Given that existing machine learning-based …
Sponsor: The First Hospital of Jilin University • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC